Flovent Diskus
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc., Johns Hopkins University, Respirent Pharmaceuticals Co Ltd.
Conditions
AsthmaBioequivalence
Phase 1
A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions
NCT05021887
Start: 2021-08-13End: 2021-11-30Target: 50Updated: 2021-08-26
A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions
NCT05397834
Start: 2022-05-11End: 2022-09-01Updated: 2022-05-31
Phase 2
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids
CompletedNCT01479621
Start: 2012-01-31End: 2013-07-31Updated: 2017-06-05
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications
CompletedNCT01576718
Start: 2012-04-30End: 2013-10-31Updated: 2018-05-08
Environmental Control as Add-on Therapy in Childhood Asthma
CompletedNCT02251379
Start: 2014-10-01End: 2018-11-30Updated: 2019-11-20